Official UK procurement notice
NP47926 Biologic, Biosimilar’s and Methotrexate Injections
Authority: The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
What is being bought13 lots · detail below
Published requirement descriptionSupply of Biologics, Biosimilars and Methotrexate Injections to NHS Scotland.
CPV: Antineoplastic and immunomodulating agents · General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents · Pharmaceutical products · Various medicinal products
How this framework works
From the published notice- Places
- up to 18 suppliers
Lots and requirements (13)Procurement structure
13 lots · 12 with a published value · same evaluation weights on every lotLot #1AdalimumabRenewalPublished value£68,840,541
- Extensions
- This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Variant bids
- not allowed
Lot #2EtanerceptRenewalPublished value£56,785,379
- Extensions
- This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Variant bids
- not allowed
Lot #3GolimumabRenewalPublished value£17,468,277
- Extensions
- This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Variant bids
- not allowed
Lot #4Infliximab Intravenous InfusionRenewalPublished value£30,991,783
- Extensions
- This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Variant bids
- not allowed
Lot #5Infliximab Subcutaneous InjectionRenewalPublished value£18,830,820
- Extensions
- This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Variant bids
- not allowed
Lot #6Methotrexate (50mg/1ml concentration) Pre-Filled Self Injection DeviceRenewalPublished value£3,719,554
- Extensions
- This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Variant bids
- not allowed
Lot #7Methotrexate (50mg/1ml concentration) Pre-Filled SyringeRenewalPublished value£2,071
- Extensions
- This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Variant bids
- not allowed
Lot #8Methotrexate (25mg/1ml concentration) Pre-Filled Self Injection DeviceRenewalLot estimate not published
- Extensions
- This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Variant bids
- not allowed
Lot #9Methotrexate (25mg/1ml concentration) Pre-Filled Self Injection SyringeRenewalPublished value£14,565
- Extensions
- This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Variant bids
- not allowed
Lot #10OmalizumabRenewalPublished value£18,669,166
- Extensions
- This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Variant bids
- not allowed
Lot #11TildrakizumabRenewalPublished value£4,231,882
- Extensions
- This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Variant bids
- not allowed
Lot #12TocilizumabRenewalPublished value£46,446,380
- Extensions
- This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Variant bids
- not allowed
Lot #13UstekinumabRenewalPublished value£68,865,598
- Extensions
- This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
- Variant bids
- not allowed
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published — the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Published sub-criteria (2)
- API Sources — 5%
- price — 95%
Published award criteria (2)
- API Sources — 5
- price — 95
- SuitabilityEconomic operators may be excluded from this competition if they are in breach of any situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015
- Technical & professional ability
(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL, PLGB, or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the start more…
date. (b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent. (c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging. (d) Potential Framework Participants are required to provide evidence that their organisation has taken steps to build their awareness of the climate change emergency and how they will respond.Minimum:(a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB, PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the more…
start date should be included in the Qualification Envelope of the ITT under the …
Competition analysis · published record, not a forecast of who will bid
How The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) runs General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents (CPV 3365) tenders for its clients — and who usually turns up
The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) procures on behalf of other bodies; its record below covers every client it has tendered for, next to the Scotland market for the same work. This notice is a framework or DPS, so only frameworks and DPS are compared. Whole-market view: General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents (CPV 3365) →
How the contest usually goes
Left: the procurement agent running this notice. Right: the market where the work is delivered. Bids and award-vs-estimate pairs are per lot, from contested frameworks and DPS only — direct awards (including PA 2023 transparency notices) report one bid by definition and are left out. On Procurement Act 2023 notices the count is the tenders assessed at the final stage, not every submission received; pairs compare like with like (VAT-exclusive, or VAT-inclusive on both sides). Empty means nothing was published, not filled in from elsewhere.
The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
Runs tenders for other bodies; the client is named in the notice, not in this record. framework/DPS notices in 36 months: 1 in CPV 3365 · 15 in division 33 (1 without competition) · 25 in all categories (2 without competition)
i
How many companies usually bid for work like this.
Middle value of published bid counts, one per lot, for this buyer or this region in the same sector.
Based on this buyer’s tenders in this industry (CPV 33), last 36 months: 16 lots. All 16 lots are from older notices, which count bids received.
Nothing is filled in from UK-wide numbers. An empty tile means nothing usable was published.
i
How often only one company bid.
Share of lots that received exactly one bid, on the same competitions as the bids figure.
Based on this buyer’s tenders in this industry (CPV 33), last 36 months: 16 lots.
High means a thin market or an incumbent that is hard to beat.
i
Do awards for work like this land above or below the estimate.
Estimate against award per lot, for this buyer or this region in the same sector.
Nothing published for this buyer in this sector: not measured on frameworks — a panel award is a ceiling, not a price.
A past pattern, not a price to bid.
i
How long buyers here take to decide after bids close.
Middle value in days from the deadline to the first award notice, on competitions that published both dates.
Nothing published for this buyer in this sector: no award dates published.
Only decided tenders count, so slow ones still waiting are not in.
i
How often this buyer changes a notice after publishing it.
Middle number of amendments per notice. Deadline extensions and corrections both count.
Nothing published for this buyer in this sector: no amendment history.
i
How often this buyer awards without a competition.
Direct or limited awards as a share of its notices that say which procedure was used. These routes are legal in defined cases. This is just the record.
Based on this buyer’s tenders in this industry (CPV 33), last 36 months: 15 notices.
Scotland · General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents (CPV 3365)
framework/DPS notices delivered in Scotland in 36 months: 1 in CPV 3365 (1 competed) · 223 in division 33 (170 competed, 3 route not published)
i
How many companies usually bid for work like this.
Middle value of published bid counts, one per lot, for this buyer or this region in the same sector.
Based on this region’s tenders in this industry (CPV 33), last 36 months: 951 lots. 9 lots are from Procurement Act 2023 notices (bids assessed, middle 5) and 942 from older notices (bids received, middle 7).
Nothing is filled in from UK-wide numbers. An empty tile means nothing usable was published.
i
How often only one company bid.
Share of lots that received exactly one bid, on the same competitions as the bids figure.
Based on this region’s tenders in this industry (CPV 33), last 36 months: 951 lots.
High means a thin market or an incumbent that is hard to beat.
i
Do awards for work like this land above or below the estimate.
Estimate against award per lot, for this buyer or this region in the same sector.
Nothing published for this region in this sector: not measured on frameworks — a panel award is a ceiling, not a price.
A past pattern, not a price to bid.
i
How long buyers here take to decide after bids close.
Middle value in days from the deadline to the first award notice, on competitions that published both dates.
Based on this region’s tenders in this industry (CPV 33), last 36 months: 3 notices.
Only decided tenders count, so slow ones still waiting are not in.
i
How much of this market goes to small and medium firms.
SME bidders where buyers published the split, otherwise SME winners.
Based on this region’s tenders in this industry (CPV 33), last 36 months: 951 lots.
i
How much work like this goes to companies based in the delivery region.
Awards in this category delivered here where the winner’s registered address is in the region.
Based on this region’s tenders in this industry (CPV 33), last 36 months: 143 awards.
Registered address, so a national firm with a local branch counts as outside.
Who you are likely to meet i
Who you may be up against.
Suppliers on this buyer’s earlier similar contracts, and suppliers whose record fits this tender.
A guess from the record. Buyers do not publish who is bidding.
i
Who you may be up against.
Suppliers on this buyer’s earlier similar contracts, and suppliers whose record fits this tender.
A guess from the record. Buyers do not publish who is bidding.
Suppliers on this authority’s earlier similar contracts, then suppliers with a matching track record — from published award history, not a bid list
By lot · 13 lots i
Likely bidders for each lot.
For each lot: the previous winner, suppliers with history on this lot, and suppliers strong in this category.
A guess from the record, not a bidder list.
i
Likely bidders for each lot.
For each lot: the previous winner, suppliers with history on this lot, and suppliers strong in this category.
A guess from the record, not a bidder list.
| Lot | Awarded / admitted | Likely suppliers |
|---|---|---|
Adalimumab£68,840,541 · CPV 33652000 Tocilizumab£46,446,380 · CPV 33650000 Ustekinumab£68,865,598 · CPV 33652000 CPV market ranking when lot-specific history is thin. | — |
|
Omalizumab£18,669,166 · CPV 33652000 Golimumab£17,468,277 · CPV 33652000 Infliximab Subcutaneous Injection£18,830,820 · CPV 33652000 CPV market ranking when lot-specific history is thin. | — |
|
Tildrakizumab£4,231,882 · CPV 33652000 CPV market ranking when lot-specific history is thin. | — |
|
Etanercept£56,785,379 · CPV 33652000 Suppliers with awards on historically similar lot scopes. | — |
|
Infliximab Intravenous Infusion£30,991,783 · CPV 33652000 CPV market ranking when lot-specific history is thin. | — |
|
Methotrexate (50mg/1ml concentration) Pre-Filled Self Injection Device£3,719,554 · CPV 33652000 CPV market ranking when lot-specific history is thin. | — |
|
Methotrexate (50mg/1ml concentration) Pre-Filled Syringe£2,071 · CPV 33652000 CPV market ranking when lot-specific history is thin. | — |
|
| CPV market ranking when lot-specific history is thin. | — |
|
Methotrexate (25mg/1ml concentration) Pre-Filled Self Injection Syringe£14,565 · CPV 33652000 CPV market ranking when lot-specific history is thin. | — |
|
Ranked by CPV market fit, scale and buyer history — historical public-sector wins, not the published bidder list or a predicted field. Lots with the same shortlist are grouped.
Suppliers with a similar track record — and how they price i
Suppliers with a similar track record, and how they price.
Suppliers matched on wins in this category, history with this buyer, location and size. Their award vs estimate is from their own past wins.
A guess from the record, not a bidder list.
i
Suppliers with a similar track record, and how they price.
Suppliers matched on wins in this category, history with this buyer, location and size. Their award vs estimate is from their own past wins.
A guess from the record, not a bidder list.
| Supplier | Evidence | Last award | Their award vs estimate | Relevance |
|---|---|---|---|---|
| Seqirus UK Ltd Large | 25 class wins | 4 months ago | at estimate n=8 | 49% |
| TAKEDA UK LIMITED Large | 4 class wins · 2 lots for this buyer | 1 months ago | no comparable pairs | 48% |
| PFIZER LIMITED Large | 12 class wins | 1 months ago | no comparable pairs | 46% |
| VIATRIS UK HEALTHCARE LIMITED Large | 1 class wins · 1 lots for this buyer | 1 months ago | no comparable pairs | 45% |
| Thermo Fisher Scientific Prionic Lelystad B.V. Large | 2 class wins | 2 months ago | 20% above n=1 | 40% |
Matched by the nightly worker on class wins, buyer history, delivery geography, scale and notice text; relevance is a 0–100% heuristic score, not a probability of bidding. “Their award vs estimate” is that supplier’s median on its own comparable single-supplier wins, CPV 3365 first. Nobody here is known to be bidding.
Coverage and what to read with care
- Each tile explains itself. The on a figure says what it is, how it is counted and which scope this notice’s own record came from (class, division, all categories, or the authority’s 24-month row). The two columns are never blended and nothing is filled from a UK-wide figure; an empty tile means the source published nothing usable. Long form: Methodology.
- Coverage. Roughly 40 % of notices publish a bid count; about half publish an ITL1 delivery location, so the market column reads the authority’s registered region when the notice has none (labelled). About 30 % of award-vs-estimate pairs are exact matches — the buyer published the award at the estimate. n is on every figure; a thin sample is muted, never hidden.
- “Match” and “relevance” are model scores from the nightly matcher, not published facts. Find a Tender does not publish who is bidding. Never shown: contact details, payment behaviour, or a recommended price.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Open admission
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 21 Sept 2026, 10:11 BST
- Last source update
- 21 Sept 2026, 10:11 BST
- Award evaluation window
- 21 Oct 2026, 12:00 BST — …
- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-077614
- Electronic trading
- e-invoicing allowed · electronic ordering · electronic payment
- Review procedure
The Authority will notify economic operators who submitted a tender or (where no deselection notification has previously been made) applied to be selected to tender, of its decision to award the framework agreement which notification will contain among other information, a summary of the reasons why the economic more…
operators was unsuccessful. The notification will incorporate a ‘standstill period’ of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority dispatches the notice(s) and the date on which the Authority proposes to conclude the relevant framework agreement. The bringing of court proceedings against the Authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued, or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer(s). The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.
Publisher note: The estimated value(s) referred to in Section II.1.5 and within all Lots cover(s) the 24 month contract duration and the 24 month extension period of the framework agreement. The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 32662. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343 A sub-contract clause has been included in this contract. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2363 Community benefits are included in this requirement. For more information see: https://www.gov.scot/policies/public-sector-procurement/community-benefits-in-procurement/ A summary of the expected community benefits has been provided as follows: It is a mandatory requirement that potential framework participants agree to support the concept, provision, and ongoing development of community benefits provision in relation to this framework. Potential framework participants are required to agree to this mandatory requirement. They are also requested to provide a summary of the community benefits that have recently been delivered within Scotland, if at all, and what impact and outcomes these have achieved. Potential framework participants are required to summarise any proposed community benefits that will be developed and delivered as part of this framework if successful or, alternatively, potential framework participants confirm that they will engage with the NHS Scotland’s Community Benefits Gateway (CBG). This gateway, developed through requests from suppliers seeking opportunities to support the delivery of community benefits within the contracting region, provides information on community benefit opportunities. The CBG is a free and easy to use online service that connects NHS Scotland suppliers with third sector community organisations within Scotland and will be used for tracking and reporting and is an approved compliant route to the realisation of community benefits. For further information please visit NHSS Community Benefit Gateway (https://www.nss.nhs.scot/procurement-and-logistics/sustainability/access-our-community-benefit-gateway/). (SC Ref:841676)
How to participate & submission route
Apply via Public Contracts Scotland- Expression of interest (EOI)
- —
- Appointment period ends
- 21 Oct 2026, 12:00 BST
- Clarification deadline
- —
- Submission channel
- {"electronicSubmission"}
- Accepted languages
- en
- Bids opened
- 21 Oct 2026, 12:00 BST
Timeline
3 published dates · Europe/London- Notice published1 day ago21 Sept 2026, 10:11 BST
- Admission / appointment period endsin 29 days · period end, not a bid countdown21 Oct 2026, 12:00 BST
- Bids openedin 29 days21 Oct 2026, 12:00 BST
Commercial outcome & contract awards
Nothing awarded yet- Awards (0)
- No award published
- Contracts (0)
- No contract published
- Bid statistics
- No aggregate bid statistics published
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Sheriff Court HouseReview body
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice; the tender pack is on the portal.